Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

The chart below shows that this ... the company quickly pivoted to another GLP-1-based weight-loss drug, liraglutide, which may be less effective than semaglutide. There is a risk that the FDA ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

"It's been interesting to watch her trend down the growth chart to ... agonists for weight loss has grown, so too has their use in children. Currently, liraglutide and semaglutide are the only ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

Fulton Financial Corporation ("Fulton") today announced that it will distribute its first quarter 2025 earnings release and accompanying charts on Tuesday, April 15, at approximately 4:30 p.m. Eastern ...

Ozempic (semaglutide) is prescribed for adults with ... Can Ozempic be used for weight loss? If so, what’s the dosing for this use? Ozempic is not approved by the Food and Drug Administration ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...